US Markets End Mixed as Silence Therapeutics, Disc Medicine, and EyePoint Lead Stock Movers
Major U.S. stock benchmarks finished mixed on Monday, with tech equities pushing the Nasdaq higher while the Dow Jones Industrial Average recorded a slight decline. Specific company announcements created notable price movements across the healthcare, steel, and technology sectors, with biotech stocks experiencing particularly large swings following buyout news and trial updates.
Silence Therapeutics plc (NASDAQ:SLN) rallied 125.58% after agreeing to a cash acquisition by Merck valued at roughly $1.3 billion. Disc Medicine Inc. (NASDAQ:IRON) climbed 38.86% following successful Phase 3 trial data for its metabolic disorder treatment bitopertin. Meanwhile, steel producer Cleveland-Cliffs Inc. (NYSE:CLF) rose 16.05% after beating third-quarter profit estimates, and Amazon.com Inc. (NASDAQ:AMZN) added 4.98% amid an analyst price target increase and an expanded supply agreement.
Conversely, EyePoint Inc. (NASDAQ:EYPT) tumbled 85.28% after its primary eye disease candidate missed its main objective in a late-stage clinical trial, prompting a 53% workforce reduction and trial termination. Looking ahead, investors will monitor FDA filing submissions from Disc Medicine, pending transaction steps for Silence Therapeutics, and corporate restructuring efforts at EyePoint.
Key points
- Silence Therapeutics plc (NASDAQ:SLN) agreed to a cash takeover by Merck for about $1.3 billion, sending shares up 125.58%.
- EyePoint Inc. (NASDAQ:EYPT) plunged 85.28% after ending a Phase 3 study early and announcing a 53% staff cut.
- Disc Medicine Inc. (NASDAQ:IRON) surged 38.86% after its key candidate met all endpoints in a Phase 3 trial.
- Cleveland-Cliffs Inc. (NYSE:CLF) jumped 16.05% after third-quarter adjusted earnings per share topped forecasts.
- Amazon.com Inc. (NASDAQ:AMZN) rose 4.98% following an analyst price target upgrade to $350 and a deal with 3M.
Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org
How we writeDisclaimerQuestions and answers
Why did Silence Therapeutics stock surge today?
Silence Therapeutics plc agreed to be acquired by Merck in a cash transaction valued at approximately $1.3 billion.
Why did EyePoint stock drop significantly?
EyePoint Inc. shares plunged after its treatment candidate failed to meet the primary visual acuity endpoint in a Phase 3 trial.
How did Cleveland-Cliffs perform in its latest earnings report?
Cleveland-Cliffs Inc. posted third-quarter adjusted earnings of 28 cents per share, beating expectations of 19 cents, despite revenue missing estimates.